Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, ≥18 y of age~* Judged to be in generally good health~* Fasting triglycerides ≥150 mg/dL to ≤499 mg/dL during screening~* Body mass index of ≥20.0 kg/m2~* No clinically significant findings in a 12-lead ECG or physical examination~* Willing and able to undergo the scheduled study procedures~* Understands study procedures and signs forms documenting informed consent to participate in the study~Exclusion Criteria:~* Laboratory test result of clinical significance~* Uncontrolled hypertension~* Clinically significant gastrointestinal, endocrine, cardiovascular, renal, hepatic, pulmonary, pancreatic, neurologic, or biliary disorder~* History of human immunodeficiency virus, hepatitis B or hepatitis C infection~* Used any medication intended to alter the lipid profile within 4 weeks of the first qualification visit~* Active systemic infection~* A condition the Investigator believes would interfere subject ability to provide informed consent and/or comply with the study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omega-3 pentaenoic acid (MAT9001) (Type: EXPERIMENTAL): 2g MAT9001 capsules twice daily with meals
- Icosapent ethyl (Vascepa) (Type: ACTIVE_COMPARATOR): 2g Vascepa capsules twice daily with meals

Based on this trial design, predict the completion outcome and termination type (if applicable).